A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

Freenome, developer of tests that identify early signs of cancer from a small sample of patient blood, is going public in a merger deal that will infuse the company with $330 million to support a ...

Freenome is taking itself public via a special purpose acquisition company, also known as a SPAC deal, to help raise funds in preparation for the planned 2026 launch of its blood-based screening tests ...

– Freenome building commercial infrastructure following recent CLIA lab certification and early access program for key health system partners, with new test launches for colorectal cancer, lung cancer ...

California-based Freenome, a cancer detection company, announced a strategic collaboration agreement with pharma giant Roche with the aim of commercializing Freenome's cancer screening technology ...

Gross margin was 69%, and adjusted gross margin was 72%. In addition, Exact Sciences shared initial results from an internal version of its colorectal cancer (CRC) blood test, showing sensitivities of ...

Accomplished industry leader brings specialized experience to advance Freenome's screening blood tests for colorectal cancer, lung cancer and additional indications BRISBANE, Calif., April 8, 2025 ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Freenome, a Bay Area biotech that is part of the increasingly competitive race to ...

– Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital – – Freenome stockholders, PCSC shareholders and PIPE ...